AZNAstraZenecaRunning, no new patients
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
ER-Positive HER2-Negative Breast Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Jun 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 3
- Patients
- 315 (final count)
- Started
- Jun 30, 2021
- Main results expected
- Jun 30, 2025
- Fully finished
- Sep 1, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1)
Measured over: From randomization until the earlier of the progression event or death (approximately 2 years)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-06-30, no fading
Raw record changes
- none yet
Trial ID NCT04964934 · record last updated 2026-09-23 · checked 2026-11-09 15:47 UTC